Search

Background: Bone metastases (BoMs) are prevalent in patients with metastatic non-small-cell lung cancer (NSCLC) however, there are limited data detailing how BoMs respond to immune checkpoint inhibitors (ICIs). The purpose of this study was to compare the imaging response to ICIs of BoMs against visceral metastases and to evaluate the effect of BoMs on survival. Materials and methods: A retrospective, multicentre cohort study was conducted in patients with NSCLC treated with nivolumab or pembrolizumab in Alberta, Canada from 2015 to 2020. The primary endpoint was the real-world organ specific progression free survival (osPFS) of bone versus visceral metastases. Visceral metastases were categorized as adrenal, brain, liver, lung, lymph node, or other intra-abdominal lesions. The secondary outcome was overall survival (OS) amongst patients with and without BoMs. Results: A total of 573 patients were included of which all patients had visceral metastases and 243 patients (42.4%) had BoMs. High PD-L1 expression was identified in 268 patients (46.8%). No significant difference in osPFS was observed between bone, liver, and intra-abdominal metastases (p=0.20 and p=0.76, respectively), with all showing shorter osPFS than other disease sites. There was no difference in the osPFS of extra-thoracic sites of disease in patients with high PD-L1 expression. There was significant discordance between visceral disease response and bone disease response to ICI (p=0.047). The presence of BoMs was an independent poor prognostic factor for OS (HR 1.26, 95%CI: 1.05-1.53, p=0.01). Conclusion: Metastatic bone, liver, and intra-abdominal lesions demonstrated inferior clinical responses to ICI relative to other sites of disease. Additionally, the presence of bone and liver metastases were independent poor prognostic factors for overall survival. This real-world data suggests that BoMs respond poorly to ICI and may require treatment adjuncts for disease control. [ABSTRACT FROM AUTHOR]

The purpose of this study was to evaluate the preimplantation surface finish of the femoral component used in total knee arthroplasty. Nine femoral components from various manufacturers were obtained for analysis. All were fixed-bearing, posterior-stabilized implants intended for cemented arthroplasty. Surface characterization involved light profilometry over multiple surface points from the condylar surface, trochlear groove, and the posterior stabilizing cam. Results revealed that the condylar surface roughness was not significantly different when comparing designs with a mean roughness average ranging from 43.6 to 116 nm. The trochlear surface was generally similar to that of the condyles in most implants, although significant differences were seen in 2 implants (P <.05). Of note, the articular surface of the stabilizing cam was uniformly rougher than the condylar surface in all implants and significantly rougher (P <.05) in 6 of the 9 components.